Form 8-K

8-K — RenovoRx, Inc.

Accession: 0001493152-26-035995

Filed: 2026-08-04

Period: 2026-08-04

CIK: 0001574094

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001574094

2026-08-04

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 4, 2026

RENOVORX,

INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-40738

27-1448452

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

2570

W El Camino Real, Suite 320

Mountain

View, CA

94040

(Address of principal executive

offices)

(Zip Code)

Registrant’s

telephone number, including area code: (650) 284-4433

N/A

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instructions A.2. below):

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title of

each class

Trading Symbol(s)

Name of each

exchange on which registered

Common Stock, $0.0001 par

value per share

RNXT

Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

8.01 Other Events.

August 4, 2026, RenovoRx, Inc. (the “Company”) issued a press release announcing the Company’s expected participation

in a JonesTrading key opinion leader webinar relating to pancreatic cancer and the Company’s technology platform to be held on

August 13, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.

Description

99.1

Press Release of RenovoRx, Inc., dated August 4, 2026

104

Cover Page Interactive Data File (embedded within the

Inline XBRL document)

-2-

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

RENOVORX, INC.

Date: August 4, 2026

By:

/s/ Shaun R. Bagai

Name:

Shaun R. Bagai

Title:

Chief Executive Officer

-3-

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

RenovoRx

to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August

13th

MOUNTAIN

VIEW, Calif., August 4, 2026 — RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT),

a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented,

FDA-cleared drug-delivery device, today announced it will participate in a JonesTrading webinar with oncology key opinion leaders (KOLs)

and Shaun Bagai, Chief Executive Officer of RenovoRx, on August 13, 2026 at 1:30 p.m. ET.

The

webinar, The Evolving Pancreatic Cancer Landscape: The Role of RenovoRx’s TAMP Platform and Emerging Clinical Advances,

will be moderated by Justin Walsh, Equity Research Analyst covering the healthcare sector at JonesTrading. He will be joined by Dae Won

Kim, MD, Medical Oncologist in Gastrointestinal Oncology at Moffitt Cancer Center, Ravi Shridhar, MD, PhD, Theranostic Program Director

in the Department of Radiation Oncology at AdventHealth Cancer Institute, and Mr. Bagai.

Clinical

Topics

●

The exciting

and rapidly evolving pancreatic cancer treatment landscape.

●

RenovoRx’s Trans-Arterial

Micro-Perfusion (TAMP) platform, enabled by the RenovoCath device, and its potential to deliver various existing and new chemotherapies

locally rather than systemically.

●

The ongoing Phase III TIGeR-PaC

clinical trial, which is evaluating intra-arterial gemcitabine delivered via RenovoCath, as a potential treatment for locally advanced

pancreatic cancer.

●

Clinical experience integrating

TAMP chemotherapy delivery via RenovoCath as a commercially available stand-alone medical device product into medical practice.

RenovoRx

Commercial and Financial Topics

●

Promising commercial

launch of RenovoCath as a stand-alone device within its FDA-cleared uses, with growing revenues and a pathway for continued revenue

expansion.

●

Increasing the number of

active commercial cancer center customers and their utilization of TAMP and RenovoCath to drive revenue and reduce the Company’s

cash burn.

Webinar

Details:

Title:

The Evolving Pancreatic Cancer Landscape: The Role of RenovoRx’s TAMP Platform and Emerging Clinical Advances

Date:

Thursday, August 13, 2026

Time:

1:30 p.m. ET

Speakers:

Dae Won Kim, MD, Moffitt Cancer

Center,

Ravi Shridhar, MD, PhD, AdventHealth Cancer Institute,

and

Shaun Bagai, Chief Executive Officer, RenovoRx

Moderator:

Justin Walsh, Equity Research Analyst, Healthcare, JonesTrading

Webcast: https://ir.renovorx.com/news-events/ir-calendar-events

For

interested individuals unable to join the webinar, a replay of the webcast will be available at https://ir.renovorx.com/news-events/ir-calendar-events.

About

RenovoCath

Based

on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic

and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion

in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding

our RenovoCath Instructions for Use (“IFU”), please see https://renovorx.com/wp-content/uploads/2026/06/IFU-10004-Rev.-H-Universal-IFU.pdf.

About

RenovoRx, Inc.

RenovoRx,

Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®,

a patented, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s

patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the

arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic

intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and

improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted

delivery of diagnostic and therapeutic agents.

RenovoRx

is actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. For its first full year of commercial

efforts in 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales and a record $563,000 of sales in the first quarter

of 2026. RenovoRx is actively working to expand the number of medical institutions initiating new RenovoCath orders, including esteemed,

high-volume National Cancer Institute-designated centers.

RenovoRx

is also evaluating its novel drug-device combination oncology product candidate intra-arterial gemcitabine delivered via RenovoCath (known

as IAG), in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division

of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath,

which is FDA-cleared for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic

drug infusion. RenovoRx anticipates full enrollment in the TIGeR-PaC trial in the very near term and final data readout in mid to late

2027.

The

IAG combination product candidate, enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial

sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years

of market exclusivity upon new drug application approval by the FDA.

For

more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.

Cautionary

Note Regarding Forward-Looking Statements

This

press release, the webinar described herein, and statements of the Company’s management and third parties made in connection therewith

contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities

Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies (including expectations for

full enrollment and data read out), (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes

for certain medical conditions or diseases, and (iii) our efforts to commercialize our RenovoCath and TAMP technology and our expected

financial results from such efforts. Statements that are not purely historical are forward-looking statements. The forward-looking statements

contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently

uncertain, outside of our control, and involve assumptions that may never materialize or may prove to be incorrect. These may include

estimates, projections, and statements relating to our research and development plans, intellectual property development, clinical trials,

our therapy platform, business plans, financing plans, objectives, and expected operating results, which are based on current expectations

and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and

adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as

“may,” “expects,” “plans,” “aims,” “anticipates,” “believes,”

“forecasts,” “aim, “ “goal,” “estimates,” “intends,” and “potential,”

or derivatives of these terms or other comparable terminology regarding RenovoRx’s statements about the future, although not all

forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and

assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among

other things: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue generating

operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional

funding; (iii) the timing of the initiation, progress, and potential results (including the results of interim analyses) of our preclinical

studies, clinical trials, and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of

our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate;

(v) that applicable regulatory authorities may disagree with our interpretation of the data, research, and clinical development plans

and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates,

including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a

pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix)

the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases

we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product

candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical

trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of

such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, needs for additional financing, our

ability to obtain additional capital and our ability to maintain the listing of our common stock on Nasdaq; (xv) the sufficiency of our

existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain

the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the scope of protection

we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates, and research

programs; (xviii) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xix)

the pricing, coverage, and reimbursement of our product candidates, if approved; and (xx) developments relating to our competitors and

our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found

in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission,

which can be accessed at https://ir.renovorx.com/sec-filings.

Forward-looking

statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking

statements to reflect subsequent events or circumstances, except as required by law.

Investor

Contact:

KCSA

Strategic Communications

Valter

Pinto or Jack Perkins

212-896-1254

RenovoRx@KCSA.com

Media

Contact:

STiR

Communications

Hannah

Williams

803-521-1214

hannah@stir-communications.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (7838 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 04, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 04, 2026

Entity File Number

001-40738

Entity Registrant Name

RENOVORX,

INC.

Entity Central Index Key

0001574094

Entity Tax Identification Number

27-1448452

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2570

W El Camino Real

Entity Address, Address Line Two

Suite 320

Entity Address, City or Town

Mountain

View

Entity Address, State or Province

Entity Address, Postal Zip Code

94040

City Area Code

(650)

Local Phone Number

284-4433

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.0001 par

value per share

Trading Symbol

RNXT

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration